PVLA

142.8502.00%
CP

Christopher P. Kiritsy

Non-Employee Independent Director

Mr. Christopher P. Kiritsy, also known as Chris, is Independent Director of Palvella Therapeutics, Inc. from September 2016. He has been a Non-Employee Independent Director of HTG Molecular Diagnostics, Inc., since January 27, 2022. He co-founded Arisaph Pharmaceuticals, Inc. since 1999 and was its Chief Executive Officer and President since June 2005 until March 2018. Mr. Kiritsy is the Founder and Managing Member of Precision Kapital, LLC, a private investment and advisory firm. He is a seasoned entrepreneur, who possesses immense business and technical experience, previously holding senior management positions in R&D, business development and finance. He was Consultant of Kos Pharmaceuticals, Inc. since May 23, 2005. He served as an Executive Vice President of Corporate Development and Chief Financial Officer of Kos Pharmaceuticals Inc., until May 20, 2005. He served as Senior Vice President of Kos Pharmaceuticals Inc. He played a key operating role in commercializing Kos' two internally developed cholesterol therapies (Niaspan® and Advicor®). During his 10-year tenure at Kos, he spearheaded more than 10 major corporate development transactions and raised approximately 500 million in public equity, including its initial public offering. In 1999, while serving as Director of Business Planning at Kos Pharmaceuticals, a non-executive officer position and before it conducted business with Triad, Mr. Kiritsy served as advisor to Mr. Jaharis in connection with his initial investment in Triad. He served as Associate Director of Product Development at the Institute of Molecular Biology, where he co-authored several publications in scientific journals. He serves as Chairman of the Board of Directors of Avaxia Biologics, Inc. He serves as an Independent Director of Pieris Pharmaceuticals, Inc. since September 22, 2016. Mr. Kiritsy joined the Pieris Pharmaceuticals, Inc. on September 22, 2016. He has been a Director of Avaxia Biologics, Inc. since April 2012. He previously served as a Board member of Melinta Pharmaceuticals, Inc. He served as a Director of Melinta Therapeutics, Inc. since August 2014. He has been a Director of Arisaph Pharmaceuticals, Inc. since 1999. He has been a member of the Board of Directors of Triad since 1999. He serves as a Member of the Advisory Board of Vatera Healthcare Partners (also known as Vatera Capital LLC). He is a seasoned entrepreneur. Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.

Positions